I was waiting for a dip and here it is, so back in again; I certainly regret not getting in earlier but for a long time I just stayed away from shares altogether, especially leverage, it was too painful. Did my head in. Relenza is a lot more accepted than before and GP's are prescribing it more often. Now there is increased awareness of treatment options we will see more antivirals prescribed every influenza season, and an increasing proportion will be Relenza and eventually, Lanamivir if all goes well. Most seasonal influenza is now resistant to Tamiflu and this will create long term pressure for alternatives.
BTA Price at posting:
$1.86 Sentiment: LT Buy Disclosure: Held
